Previous close | 240.00 |
Open | 240.40 |
Bid | 241.60 x 0 |
Ask | 241.80 x 0 |
Day's range | 240.40 - 242.20 |
52-week range | 235.80 - 318.00 |
Volume | |
Avg. volume | 31,574 |
Market cap | 183.555B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 16.91 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.60 (4.00%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.
PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.